
ELCC 2025 Industry Satellite Symposium



Promising New Targets and ADCs in Development for NSCLC

Friday, 28 March 2025 16:45-17:45 CET Room N02, Hall 7, Level 7.3, Paris Expo Porte de Versailles, Paris, France Please join us for a satellite symposium as two experts discuss promising late-stage and early-stage antibody-drug conjugates (ADCs) under investigation for non-small cell lung cancer (NSCLC).



Are we making progress? Updates on late-stage ADCs in NSCLC

David Planchard, MD, PhD

Head of Thoracic Cancer Group Department of Medical Oncology Gustave Roussy Villejuif, France



What's next in NSCLC? New targets and ADC innovations

Anna Minchom, MB BCh, FRCP, MD (Res)

Consultant Medical Oncologist, Drug Development Phase I Unit The Royal Marsden Hospital and The Institute of Cancer Research London, United Kingdom



Funded by Pfizer. For healthcare professionals only.

© 2025 Pfizer Inc. All rights reserved. PP-SVN-GLB-0005. January 2025.